AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.



Biotechnology

AC Immune

Andrea Pfeifer

Christopher R.

Madiha Derouazi

Nuno Mendonça

Bojana Portmann

Julien Rongère

Marie Kosco-Vilbois

Piergiorgio Donati

Christopher Roberts

Jean-Fabien Monin

Howard Donovan

The Scientific & Research Team at AC Immune is responsible for developing and advancing the company’s pipeline of therapeutic and diagnostic candidates targeting neurodegenerative diseases. This multidisciplinary team combines expertise in drug discovery, clinical research, data science, and preclinical development to support the company's innovative platforms, SupraAntigen™ and Morphomer™. They collaborate closely with strategic partners to accelerate the progression of treatments through clinical trials, ensuring rigorous scientific validation at every stage.

Scientific & Research Team

Leadership Team

Finance Team

Scientific & Research Team

About

Team members

Other teams at AC Immune

Leadership Team

Finance Team